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AB0052 INCREASED PERIPHERAL CD8+ T CELL RESPONSES IN SLE BY LOW-DOSE IL-2 TREATMENT
R. Zhang, J. He, X. Sun, Y. Zou, Y. Gan, Z. Li. Peking University People's Hospital, Beijing, China Background: CD8+ T cell responses to viral pathogens is crucial for the prompt resolution of acute infections. SLE patients are more likely to have infections due to suppression of immune system by long-term glucocorticoid and immunosuppressive agent intake. Our previous study showed that low-dose IL-2 is effective in SLE. Objectives: The present study is to evaluate the potential anti-infection effect of low-dose IL-2 in refractory SLE patients. Methods: Nine refractory SLE patients and 9 health controls (HCs) were recruited three cycles of 1 million IU recombinant human IL-2 (rhIL-2), administered subcutaneously every other day for 2 weeks, followed by a 2-week break. The disease activitise were evaluated by rheumatologist. The frequencies of T cell subsets were assayed by flow cytometry. Virus-specific CD8 T cells responses were determined based on TNF-a, IFN-g and Grazmy B producing CD8 T cells upon CMV-EBV-Flu (CEF) viral peptide pool stimulation and subsequent intracellular staining. Results: Most patients showed good clinical responses after three cycles of low-dose IL-2 treatment. Clinical improvement was observed in SIR-4 response, improved complement 3 and 4 serum level and decreased anti-ds-DNA serum level. Functional profiling of CD8 T cells in low-dose IL-2 treated patients revealed an increased in the frequencies of CEF viral peptide specific TNF-a + and Grazmy-B + CD8 T cells. Moreover, low-dose IL-2 treated patients showed stronger antigen-specific response demonstrated by an increased stimulated/nonstimulate TNF-a-producing CD 8 T cells proliferation fold. Compared with HCs, SLE patients showed significantly lower frequencies of CEF specific Grazmy-B producing CD8 T cell, and treatment with low-dose IL-2 significantly increased the frequency of these Grazmy-B + CD8 T cells in SLE patients. Conclusions: Low-dose IL-2 treatment was effective and safe in refractory SLE patients. Virus-specific antigen-specific CD8 T cell response could be enhanced upon this treatment which might be potentially valuable in anti-infection in SLE. Background: Rheumatic manifestation such as arthritis, spondylitis are the most common frequent extra-intestinal manifestations of inflammatory bowel disease (IBD), affecting 6 to 46% of patients. IBD is an umbrella term with two most prevalent entities namely Crohn's disease and Ulcerative colitis, defined as idiopathic chronic, relapsing and remitting inflammatory condition of intestinal tract. MMP-9, a matrixin is involved in the degradation of extracellular matrix promoting inflammation. Studies on MMP-9 knockout mice illustrated protection from collagen induced rheumatoid arthritis (RA) and Dextran sulphate sodium (DSS) induced colitis. Furthermore elevated MMP9 levels can be found in the synovial fluid of RA patients as well as IBD patients signifying that targeting MMP9 may have therapeutic importance. Mangiferin, an active component of Mango has demonstrated anti-inflammatory effects in the treatment of rheumatoid arthritis with low side-effects [1, 2] ; but its usefulness in chronic remission and relapse phases of human IBD i.e. chronic DSS model have not screened till date. Objectives: We investigated the therapeutic potential of Mangiferin; in a clinical relevant chronic model of DSS induced colitis in mice. Methods: Female BALB/c mice (8 to 12 wks) were randomized into four groups. Colitis was induced by cyclical administration of 5% DSS to mice i.e. 3 cycles of DSS with every cycle consisting of 7 days DSS followed by 7 days of autoclaved drinking water (7D DSS + 7D water). Group I (Normal control): free access to autoclaved drinking water. Group II (DSS control): free access to 5% DSS. Group III (DSS + Mangiferin_30mg/kg): free access to 5% DSS + oral Mangiferin at 30mg/kg. Group IV (DSS + Mangiferin_60mg/kg): free access to 5% DSS + oral Mangiferin at 60mg/kg. Mangiferin treatment was initiated following second cycle of DSS (i.e. Day 21); after assuring that colitis relapsed in mice. One fragment of the colon was fixed in 10% neutral buffered formalin for microscopic examination while the remaining tissue was divided into parts and stored at -70°C for assessment of biochemical markers of oxidative stress and inflammatory cytokines such as TNF-α, IL-1β, MMP-9. Results: Mangiferin treatment ameliorated the clinical parameters (body weight loss, stool consistency, occult blood), reduced microscopic damage (re-established mucosal architecture, abridged neutrophil infiltration), restored epithelial barrier integrity (diminished goblet cell loss), attenuated biochemical markers of oxidative stress (GSH, CAT, SOD, MDA, MPO), crucial inflammatory cytokines TNF-α, IL-1β and attenuates MMP-9 levels implicated in the pathogenesis of arthritis and IBD. Conclusions: Considering the beneficial effects of Mangiferin in arthritis and IBD, we suggest that it would be valuable to use Mangiferin in IBD patients with arthritis as its extra-intestinal manifestation. Background: CXCL4 is a chemokine produced by activated platelets and immune cells. Several studies have reported that CXCL4 plays a critical role on physiological processes since it affects the proliferation and maturation of megakaryocytic and hematopoietic progenitor cells, regulates coagulation and wound healing, displays anti-tumoral and angiostatic activity and induces immune cell modulation. Dysregulation of these processes causes the disturbance of the immune system and homeostasis, and might lead to pathological conditions. Indeed, a strong correlation was previously found between elevated CXCL4 levels in the circulation and the clinical features of patients with systemic sclerosis (SSc) (1). Dendritic cells are essential players in innate defence and bridging towards adaptive immune responses, thereby contributing to both immune activation and maintenance of homeostasis. Objectives: Considering previous observations on the association of dendritic cells and T-cell dysfunction in SSc, we here investigated the effect of CXCL4 on monocyte-derived DC (moDC) differentiation, on Toll-like receptor (TLR)-mediated responses and on activation of polyclonal and antigen-specific CD8 + T-cells.
